Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
First-In-Class But Low Revenues
Executive Summary
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.